- Activity pressure is positive on the latest completed week.
ACRV
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
Acrivon Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
Latest close
1.50 USD
-6.3%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -11.3% below the Trend Line and sits at 12.7% of its 52-week range. The latest completed week returned -6.3%, after a -12.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 54/100. Near-term considerations: earnings are due in 10d.
Setup score
30
out of 100
Latest Close
1.50 USD
31 Jul 2026
1W Return
-6.3%
latest completed week
4W Return
-12.8%
short-term follow-through
12W Return
-24.2%
quarterly tape
Trend Breadth
30.8%
16 of 52 weeks active
Volume Ratio
1.0x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-6.3%
Latest completed week; four-week move -12.8%.
Indicator stack
17/100
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
54/100
59 relevant articles in the latest sentiment read.
Event risk
10d
Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -11.3% below the Trend Line and sits at 12.7% of its 52-week range. The latest completed week returned -6.3%, after a -12.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2012-week average 0.23
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -12.8% over four weeks, -24.2% over 12 weeks, and 19.0% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year16
Trend breadth30.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.11Latest activity-pressure read.
Pressure change688.2%Four-week change in activity pressure.
Leadership-22.92Latest relative-leadership reading.
RS change-57.0%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 67%
Model confidence 64%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength75/100Blend of value, momentum, and quality. Underlying universe rank 26; rank 1 is best.
Value62/100Relative valuation strength. Underlying universe rank 39; rank 1 is best.
Quality61/100Profitability and accounting quality. Underlying universe rank 40; rank 1 is best.
Momentum62/100Medium-term price momentum. Underlying universe rank 39; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -171.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -98.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 2/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment54/100
Weighted news tone is neutral across 59 relevant articles.
13 positive · 42 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-57.9%Distance below the 52-week high.
13-week volatility7.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher13 of 2613 weeks finished lower.
Best week+14.3%Week of 3 Apr.
Worst week-19.9%Week of 27 Mar.
Latest week-6.3%Week of 31 Jul.
Shape of recent returns
Strong gains8
Modest gains5
Flat weeks0
Modest losses3
Sharp losses10
Recent vol7.8%13-week weekly-return volatility.
Base vol9.5%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew7.4% / -7.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape35/100
Trend, activity pressure, participation, and risk combine to a 35/100 tape read.
Indicator analysis29/100Latest 12-week confirmation: trend 0/12, activity pressure 10/12, relative leadership 0/12.
Activity pressure 0.20; No reversal markers Factors65/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 46; Small Cap Core rank 46 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment54/100Weighted news tone is neutral across 59 relevant articles.
Acrivon Therapeutics Inc (ACRV) Technical Analysis: Support, Resistance, Indicators & Moving Averages Insiders50/100No recent insider transaction evidence is stored.
Earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 1.50 USD | -6.3% | 1.69 USD | 4.53 USD | 0.11 | -22.92 | 2.1M | Off |
| 24 Jul 2026 | 1.60 USD | -8.6% | 1.72 USD | 4.59 USD | 0.36 | -17.38 | 969.1K | Off |
| 17 Jul 2026 | 1.75 USD | -10.7% | 1.75 USD | 4.66 USD | 0.48 | -11.20 | 3.5M | Off |
| 10 Jul 2026 | 1.96 USD | 14.0% | 1.76 USD | 4.73 USD | 0.33 | -4.61 | 3.2M | Off |
| 3 Jul 2026 | 1.72 USD | 2.4% | 1.78 USD | 4.80 USD | 0.01 | -14.60 | 1.3M | Off |
| 26 Jun 2026 | 1.68 USD | 7.0% | 1.80 USD | 4.86 USD | -0.11 | -15.82 | 1.8M | Off |
| 19 Jun 2026 | 1.57 USD | 6.1% | 1.83 USD | 4.93 USD | -0.10 | -24.78 | 1.6M | Off |
| 12 Jun 2026 | 1.48 USD | 3.5% | 1.85 USD | 5.01 USD | 0.03 | -27.26 | 1.3M | Off |
| 5 Jun 2026 | 1.43 USD | -10.6% | 1.88 USD | 5.08 USD | 0.19 | -28.21 | 2.1M | Off |
| 29 May 2026 | 1.60 USD | -8.6% | 1.89 USD | 5.15 USD | 0.41 | -23.56 | 1.4M | Off |
| 22 May 2026 | 1.75 USD | -1.1% | 1.91 USD | 5.22 USD | 0.57 | -13.90 | 2.8M | Off |
| 15 May 2026 | 1.77 USD | -10.6% | 1.92 USD | 5.29 USD | 0.67 | -11.78 | 2.3M | Off |
| 8 May 2026 | 1.98 USD | -5.3% | 1.92 USD | 5.36 USD | 0.62 | -1.44 | 3.1M | Off |
| 1 May 2026 | 2.09 USD | 9.4% | 1.91 USD | 5.44 USD | 0.21 | 10.06 | 2.9M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.